

Bugworks Research, Cytecure Cancer Hospitals collaborate on immuno-onco therapies

19 September 2022 | News

The outcome of this translational research will guide the first-in-human trials, expected to commence in early 2024



Bengaluru-based startup Bugworks Research and Cytecure Cancer Hospitals have announced first-of-its-kind collaboration. Bugworks develops best-in-class, novel therapies for cancer and infectious diseases and has set up a dedicated research centre within Cytecure, which is committed to excellence in treating cancer patients.

The coming together of a leading innovator in drug discovery and a state-of-the-art cancer hospital promises to be a game changer in saving countless human lives. Bugworks' drug discovery engine coupled with Cytecure's excellence in delivering optimal clinical outcomes will offer differentiated solutions to patients all over the world.

Bugworks' current research in immuno-oncology centres around modulating the tumour microenvironment that includes adenosine antagonism - an area of research with applications across many solid tumours. The drug candidates from this research will undergo translational testing on patient-derived tumours in the *ex vivo* laboratories at Cytecure, before progressing to first-in-human clinical studies.